ArticleESC heart failure2022
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients.Clinical drug investigation · 2024Pooled it
- Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.Future cardiology · 2026Review
- Pathogenesis and Therapeutic Advances in Heart Failure with Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2026Review
- Review
- Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities.ESC heart failure · 2025Article
- Article
- Efficacy and safety of roxadustat for treating anaemia in patients with chronic kidney disease and heart failure: a retrospective cohort study.Clinical kidney journal · 2025Article
- Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- Glycnsisitin A: A promising bicyclic peptide against heart failure that facilitates TFRC-mediated uptake of iron in cardiomyocytes.Acta pharmaceutica Sinica. B · 2024Article
- Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure.European journal of medical research · 2024Review
- Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.Heart failure reviews · 2024Review
- Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- Evaluation of a pharmacist-provider collaborative clinic for treatment of iron deficiency in patients with heart failure.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023Article
- A year in heart failure: updates of clinical and preclinical findings.ESC heart failure · 2023Review
- Determinants and treatments of heart failure after transcatheter aortic valve implantation: moving up a notch.ESC heart failure · 2023Review
- Treatment of Iron Deficiency in Heart Failure.Current cardiology reports · 2023Review
- The Importance of the Nephrologist in the Treatment of the Diuretic-Resistant Heart Failure.Life (Basel, Switzerland) · 2023Review
- Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?Life (Basel, Switzerland) · 2023Article
- Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Current heart failure reports · 2022Review
- Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). METHODS AND
resultsWe conducted a retrospective, single-centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100-300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5-fold, 1.6-fold, and 1.1-fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2-2.7) to 1.9 (IQR: 1.5-2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05).
conclusionsIntravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.